Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

267 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas.
Chong EA, Penuel E, Napier EB, Lundberg RK, Budde LE, Shadman M, Matasar MJ, Bartlett NL, Flinn IW, Bosch F, Fay K, Goy A, Kumar A, Nastoupil LJ, Wei MC, Wu M, Yin S, Fraietta JA, Chong ER, Schuster SJ. Chong EA, et al. Among authors: schuster sj. Blood Adv. 2024 Nov 21:bloodadvances.2024013640. doi: 10.1182/bloodadvances.2024013640. Online ahead of print. Blood Adv. 2024. PMID: 39571171
Retrospective Cohort Study of Novel Oral Agents Lenalidomide and Duvelisib For Relapsed or Refractory Mycosis Fungoides and Sézary Syndrome.
Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK. Elghawy O, et al. Among authors: schuster sj. J Am Acad Dermatol. 2024 Nov 16:S0190-9622(24)03212-2. doi: 10.1016/j.jaad.2024.10.095. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39557080 No abstract available.
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies.
Sehn LH, Bartlett NL, Matasar MJ, Schuster SJ, Assouline SE, Giri P, Kuruvilla J, Shadman M, Cheah CY, Dietrich S, Fay K, Ku M, Nastoupil LJ, Wei MC, Yin S, To I, Kaufman D, Kwan A, Penuel E, Bolen CR, Budde LE. Sehn LH, et al. Among authors: schuster sj. Blood. 2024 Oct 24:blood.2024025454. doi: 10.1182/blood.2024025454. Online ahead of print. Blood. 2024. PMID: 39447094
Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.
Elghawy O, Cao M, Xu J, Landsburg DJ, Svoboda J, Nasta SD, Chong EA, Schuster SJ, Thomas CJ, Carter JS, Tavakkoli M, Ruella M, Barta SK. Elghawy O, et al. Among authors: schuster sj. Cancers (Basel). 2024 Oct 9;16(19):3430. doi: 10.3390/cancers16193430. Cancers (Basel). 2024. PMID: 39410047 Free PMC article.
Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease.
Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ. Schneider M, et al. Among authors: schuster sj. Clin Lymphoma Myeloma Leuk. 2024 Sep 6:S2152-2650(24)01803-2. doi: 10.1016/j.clml.2024.08.010. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39353813
Local Radiation Enhances Systemic CAR T Cell Efficacy by Augmenting Antigen Cross-Presentation and T-cell Infiltration.
Kostopoulos N, Costabile F, Krimitza E, Beghi S, Goia D, Perales-Linares R, Thyfronitis G, LaRiviere MJ, Chong EA, Schuster SJ, Maity A, Koumenis C, Plastaras JP, Facciabene A. Kostopoulos N, et al. Among authors: schuster sj. Blood Adv. 2024 Aug 30:bloodadvances.2024012599. doi: 10.1182/bloodadvances.2024012599. Online ahead of print. Blood Adv. 2024. PMID: 39213422
Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.
Chong EA, Kumashie KG, Chong ER, Fabrizio J, Gupta A, Svoboda J, Barta SK, Walsh KM, Napier EB, Lundberg RK, Nasta SD, Gerson JN, Landsburg DJ, Gonzalez J, Gaano A, Weirick ME, McAllister CM, Awofolaju M, John GN, Kammerman SC, Novacek J, Pajarillo R, Lundgreen KA, Tanenbaum N, Gouma S, Drapeau EM, Adamski S, D'Andrea K, Pattekar A, Hicks A, Korte S, Sharma H, Herring S, Williams JC, Hamilton JT, Bates P, Hensley SE, Prak ETL, Greenplate AR, Wherry EJ, Schuster SJ, Ruella M, Vella LA. Chong EA, et al. Among authors: schuster sj. J Infect Dis. 2024 Jul 25;230(1):15-27. doi: 10.1093/infdis/jiae106. J Infect Dis. 2024. PMID: 39052709
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Ahmed N, Wesson W, Lutfi F, Porter DL, Bachanova V, Nastoupil LJ, Perales MA, Maziarz RT, Brower J, Shah GL, Chen AI, Oluwole OO, Schuster SJ, Bishop MR, McGuirk JP, Riedell PA. Ahmed N, et al. Among authors: schuster sj. Blood Adv. 2024 Oct 22;8(20):5346-5354. doi: 10.1182/bloodadvances.2023012549. Blood Adv. 2024. PMID: 39042880 Free PMC article.
267 results